Overview

This phase II study is aim to investigate the efficacy, resistance mechanism, safety profile of first-line lorlatinib in China advanced ALK+ non-small cell lung cancer (NSCLC). Participants will receive continuous daily PO dosing of lorlatinib 100mg QD.

Eligibility

Inclusion Criteria:

Inclusion Criteria of CROWN Criteria (CC) Cohort

        Subjects must meet all of the following inclusion criteria to be eligible for enrollment
        into the study:
          1. Diagnosis:
               1. Study Population: Patients with histologically or cytologically confirmed
                  diagnosis of locally advanced [(Stage IIIB/C not amenable for multimodality
                  treatment) or metastatic (Stage IV) by American Joint Committee on Cancer (AJCC)
                  v 7.0] ALK-positive NSCLC where ALK status is determined by the Ventana ALK
                  (D5F3) Companion Diagnostic (CDx) IHC test performed on the Ventana ULTRA or XT
                  Platforms, FISH, PCR, or next generation sequencing (NGS), or circulating tumor
                  DNA (ctDNA).
               2. Tumor Requirements: At least 1 extracranial measurable target lesion per RECIST
                  v. 1.1 that has not been previously irradiated. CNS metastases are allowed if
                  asymptomatic and:
                    1. Either untreated and not currently requiring corticosteroid treatment, or on
                       a stable or decreasing dose of ≤10 mg QD prednisone or equivalent; or
                    2. Local treatment has been completed with full recovery from the acute effects
                       of radiation therapy or surgery prior to randomization, and if
                       corticosteroid treatment for these metastases has been withdrawn for at
                       least 4 weeks with neurological stability; or
                    3. In case of leptomeningeal disease (LMD) or carcinomatous meningitis (CM) if
                       visualized on magnetic resonance imaging (MRI), or if baseline CSF positive
                       cytology is available.
               3. Tissue Requirements: All patients must have an archival formalin fixed, paraffin
                  embedded (FFPE) tissue specimen available and collected prior to randomization.
                  If archived tissue is unavailable, then a mandatory de novo biopsy must be
                  performed.
          2. No prior systemic NSCLC treatment for advanced (Stage IIIB/C not amenable for
             multimodality treatment) or metastatic (Stage IV) disease, including molecularly
             targeted agents (e.g., ALK TKIs), angiogenesis inhibitors, immunotherapy, or
             chemotherapy. Prior treatment for earlier Stages of the NSCLC only allowed if
             completed more than 12 months prior to randomization.
          3. Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0, 1, or 2.
          4. Age ≥18 years.
          5. Adequate Bone Marrow Function, including:
               1. Absolute Neutrophil Count (ANC) ≥ 1,500/mm3 or ≥1.5 x 109/L;
               2. Platelets ≥100,000/mm3 or ≥100 x 109/L;
               3. Hemoglobin ≥9 g/dL.
          6. Adequate Pancreatic Function, including:
               1. Serum total amylase ≤1.5 x upper limit of normal (ULN)*;
               2. Serum lipase ≤1.5 x ULN. *if total amylase >1.5 x ULN, but pancreatic amylase is
                  within the ULN, then patient may be enrolled.
          7. Adequate Renal Function, including:
             a. Serum creatinine ≤1.5 x ULN or estimated creatinine clearance ≥60 mL/min as
             calculated using the method standard for the institution.
          8. Adequate Liver Function, including:
               1. Total serum bilirubin ≤1.5 x ULN;
               2. Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤2.5 x ULN
                  (≤5.0 x ULN in case of liver metastases).
          9. Acute effects of prior radiotherapy resolved to baseline severity or to CTCAE Grade ≤1
             except for AEs that in the investigator's judgment do not constitute a safety risk for
             the patient.
         10. Serum pregnancy test (for females of childbearing potential) negative at screening.
             Female patients of non-childbearing potential must meet at least 1 of the following
             criteria:
               1. Achieved postmenopausal status, defined as follows: cessation of regular menses
                  for at least 12 consecutive months with no alternative pathological or
                  physiological cause (which may be confirmed with a serum follicle-stimulating
                  hormone [FSH] level confirming the postmenopausal state if appropriate);
               2. Have undergone a documented hysterectomy and/or bilateral oophorectomy;
               3. Have medically confirmed ovarian failure. All other female patients (including
                  female patients with tubal ligations) are considered to be of childbearing
                  potential.
         11. Evidence of a personally signed and dated informed consent document indicating that
             the patient (or a legally acceptable representative) has been informed of all
             pertinent aspects of the study.
         12. Willing and able to comply with scheduled visits, treatment plans, laboratory tests
             and other procedures.
        Inclusion Criteria of Compassionate use (CU) Cohort
          1. Diagnosed as ALK-positive NSCLC as in CC cohort, but not fulfilled CC cohort inclusion
             criteria 2~9 as above mentioned.
          2. No prior ALK TKI treatment for advanced (Stage IIIB/C not amenable for multimodality
             treatment) or metastatic (Stage IV) disease (e.g., alectinib, brigatinib).
          3. Serum pregnancy test (for females of childbearing potential) negative at screening.
          4. Evidence of a personally signed and dated informed consent document indicating that
             the patient (or a legally acceptable representative) has been informed of all
             pertinent aspects of the study.
          5. Willing and able to comply with scheduled visits, treatment plans, laboratory tests
             and other procedures.
        Exclusion Criteria:
        Subjects presenting with any of the following characteristics/conditions will not be
        included in this clinical study:
          1. Spinal cord compression unless the patient has good pain control attained through
             therapy, and there is stabilization or recovery of neurological function for the 4
             weeks prior to randomization.
          2. Major surgery within 4 weeks prior to randomization. Minor surgical procedures (e.g.,
             port insertion) are not excluded, but sufficient time should have passed for adequate
             wound healing.
          3. Radiation therapy within 2 weeks prior to randomization, including stereotactic or
             partial brain irradiation. Patients who complete whole brain irradiation within 4
             weeks prior to randomization or palliative radiation therapy outside of the CNS within
             48 hours prior to randomization will also not be included in the study.
          4. Gastrointestinal abnormalities, including inability to take oral medication;
             requirement for intravenous alimentation; prior surgical procedures affecting
             absorption including total gastric resection or lap band; active inflammatory
             gastrointestinal disease, chronic diarrhea, symptomatic diverticular disease;
             treatment for active peptic ulcer disease in the past 6 months; malabsorption
             syndromes.
          5. Known prior or suspected severe hypersensitivity to study drugs or any component in
             their formulations.
          6. Active and clinically significant bacterial, fungal, or viral infection including
             hepatitis B virus (HBV) or hepatitis C virus (HCV) (e.g., in case of known HBsAg or
             HCV antibody positivity), known human immunodeficiency virus (HIV), or acquired
             immunodeficiency syndrome (AIDS)-related illness.
          7. Clinically significant vascular (both arterial and venous) and non-vascular cardiac
             conditions, (active or within 3 months prior to enrollment), which may include, but
             are not limited to:
               1. Arterial disease such as cerebral vascular accident/stroke (including Transient
                  Ischemic Attack -TIA), myocardial infarction, unstable angina;
               2. Venous diseases such as cerebral venous thrombosis, symptomatic pulmonary
                  embolism;
               3. Non-vascular cardiac disease such as congestive heart failure (New York Heart
                  Association Classification Class ≥ II), second-degree or third-degree AV block
                  (unless paced) or any AV block with PR >220 msec; or ongoing cardiac dysrhythmias
                  of NCI CTCAE Grade ≥2, uncontrolled atrial fibrillation of any grade, bradycardia
                  defined as <50 bpm (unless patient is otherwise healthy such as long-distance
                  runners, etc.), machine-read Electrocardiogram (ECG) with QTc >470 msec, or
                  congenital long QT syndrome.
          8. Patients with predisposing characteristics for acute pancreatitis according to
             investigator judgment (e.g., uncontrolled hyperglycemia, current gallstone disease) in
             the last month prior to randomization.
          9. History of extensive, disseminated, bilateral or presence of Grade 3 or 4 interstitial
             fibrosis or interstitial lung disease including a history of pneumonitis,
             hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease,
             obliterative bronchiolitis, and pulmonary fibrosis.
         10. Evidence of active malignancy (other than NSCLC, non-melanoma skin cancer, or
             localized prostate cancer or any in situ cancer which does not currently require
             treatment) within the last 3 years prior to randomization.
         11. Concurrent use of any of the following food or drugs (consult the sponsor if in doubt
             whether a food or a drug falls into any of the above categories) within 12 days prior
             to the first dose of lorlatinib.
               1. Known strong CYP3A inhibitors (e.g., strong CYP3A inhibitors: grapefruit juice or
                  grapefruit/grapefruit related citrus fruits [eg, Seville oranges, pomelos],
                  boceprevir, cobicistat, conivaptan, itraconazole, ketoconazole, posaconazole,
                  ritonavir alone and with danoprevir or elvitegravir or indinavir or lopinavir or
                  paritaprevir or ombitasvir or dasabuvir or saquinavir or tipranavir, telaprevir,
                  troleandomycin, and voriconazole. The topical use of these medications (if
                  applicable), such as 2% ketoconazole cream, is allowed.
               2. Known CYP3A substrates with narrow therapeutic index, such as astemizole,
                  terfenadine, cisapride, pimozide, quinidine, tacrolimus, cyclosporine,
                  sirolimus, alfentanil, fentanyl (including transdermal patch) or ergot alkaloids
                  (ergotamine, dihydroergotamine) (withdrawn from US market).
               3. Known strong CYP3A inducers (e.g., carbamazepine, enzalutamide, mitotane,
                  phenytoin, rifampin, St. John's Wort). d. Known P-gp substrates with a narrow
                  therapeutic index (e.g., digoxin).
         12. Other severe acute or chronic medical or psychiatric condition, including recent
             (within the past year) or active suicidal ideation or behavior, or laboratory
             abnormality that may increase the risk associated with study participation or
             investigational product administration or may interfere with the interpretation of
             study results and, in the judgment of the investigator, would make the patient
             inappropriate for entry into this study.
         13. Patients who are investigational site staff members directly involved in the conduct
             of the study and their family members, site staff members otherwise supervised by the
             Investigator, or patients who are Pfizer employees, including their family members,
             directly involved in the conduct of the study.
         14. Participation in other studies involving investigational drug(s) within 2 weeks prior
             to study entry and/or during study participation.
         15. Pregnant female patients; breastfeeding female patients; fertile male patients and
             female patients of childbearing potential who are unwilling or unable to use a highly
             effective method of contraception as outlined in this protocol for the duration of the
             study and for at least 97 days, if male or 35 days if female, after the last dose of
             investigational product under lorlatinib.